Related Experiment Video
Updated: Aug 15, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Transcriptomics analysis of LINC02202/XBP1 axis in melanoma: Implications for drug targeting and PD-1 monoclonal
Yuanyuan Shang1, Haiqian Yang2, Jian Cui3
1School of Public Health, Ningxia Medical University, Yinchuan, China.
Abstract:
Malignant melanoma (MM) is a highly aggressive and deadly form of skin cancer, primarily caused by recurrence and metastasis. Therefore, it is crucial to investigate the regulatory mechanisms underlying melanoma recurrence and metastasis. Our study has identified a potential targeted regulatory relationship between LINC02202, miR-526b-3p and XBP1 in malignant melanoma. Through the regulation of the miR-526b-3p/XBP1 signalling pathway, LINC02202 may play a role in tumour progression and immune infiltration and inhibiting the expression of LINC02202 can increase the efficacy of immunotherapy for melanoma. Our findings shed light on the impact of LINC02202/XBP1 on the phenotype and function of malignant melanoma cells. Furthermore, this study provides a theoretical foundation for the development of novel immunotherapy strategies for malignant melanoma.
Insights
This study reveals LINC02202 regulates malignant melanoma progression and immune infiltration via the miR-526b-3p/XBP1 pathway. Inhibiting LINC02202 may enhance melanoma immunotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Malignant melanoma (MM) is an aggressive skin cancer characterized by high rates of recurrence and metastasis.
- Understanding the molecular mechanisms driving MM progression is critical for developing effective treatments.
Purpose of the Study:
- To investigate the regulatory role of LINC02202 in malignant melanoma.
- To elucidate the relationship between LINC02202, miR-526b-3p, and XBP1 in melanoma.
- To explore the potential of targeting LINC02202 for improving melanoma immunotherapy.
Main Methods:
- Bioinformatic analysis to identify potential regulatory relationships.
- In vitro experiments to validate the interactions between LINC02202, miR-526b-3p, and XBP1.
- Assessment of tumor progression and immune infiltration markers.
- Evaluation of LINC02202 inhibition on melanoma cell phenotype and immunotherapy response.
Main Results:
- A targeted regulatory network involving LINC02202, miR-526b-3p, and XBP1 was identified in malignant melanoma.
- LINC02202 influences melanoma cell phenotype, tumor progression, and immune infiltration through the miR-526b-3p/XBP1 signaling pathway.
- Inhibiting LINC02202 expression was shown to enhance the efficacy of melanoma immunotherapy.
Conclusions:
- LINC02202 plays a significant role in malignant melanoma progression and immune evasion.
- Targeting LINC02202 offers a promising strategy for novel melanoma immunotherapy.
- This research provides a theoretical basis for developing new therapeutic approaches for melanoma.
